# Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car

Source: https://onco.cc/trials/nct06947928/  
OnCo record `nct06947928` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Pembrolizumab in merkel cell carcinoma, run by TuHURA Biosciences, Inc., now recruiting.

## Summary

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma is a phase 2/3 interventional study registered as NCT06947928 by TuHURA Biosciences, Inc., with 118 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: IFx-Hu2.0, Placebo, Pembrolizumab. Conditions listed: Advanced Or Metastatic Merkel Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06947928
- Phase: 2/3
- Setting: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma
- Sponsor: TuHURA Biosciences, Inc.
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT06947928: https://clinicaltrials.gov/study/NCT06947928

## Connected records

- cancers: [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06947928.json